CONCORDBIOPharmaceuticals
Concord Biotech Ltd — Profit & Loss Statement
₹1018.40
-2.34%
Concord Biotech Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 1.09 Cr | -0.25 Cr | — |
| Tax Rate For Calcs | 0.25 | 0.25 | 0.26 | 0.26 | — |
| Normalized EBITDA | 549.46 Cr | 468.71 Cr | 376.31 Cr | 294.01 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 371.64 Cr | 308.10 Cr | 240.09 Cr | 174.93 Cr | — |
| Reconciled Depreciation | 54.37 Cr | 53.59 Cr | 54.03 Cr | 50.05 Cr | — |
| Reconciled Cost Of Revenue | 305.51 Cr | 229.20 Cr | 197.07 Cr | 177.92 Cr | — |
| EBITDA | 549.46 Cr | 468.71 Cr | 380.56 Cr | 293.05 Cr | — |
| EBIT | 495.08 Cr | 415.12 Cr | 326.52 Cr | 243.00 Cr | — |
| Net Interest Income | -0.53 Cr | -2.55 Cr | -0.74 Cr | -1.35 Cr | — |
| Interest Expense | 0.53 Cr | 2.55 Cr | 4.51 Cr | 5.48 Cr | — |
| Normalized Income | 371.64 Cr | 308.10 Cr | 236.93 Cr | 175.63 Cr | — |
| Net Income From Continuing And Discontinued Operation | 371.64 Cr | 308.10 Cr | 240.09 Cr | 174.93 Cr | — |
| Total Expenses | 748.13 Cr | 638.97 Cr | 525.89 Cr | 472.31 Cr | — |
| Diluted Average Shares | 10.46 Cr | 10.46 Cr | 10.46 Cr | 10.46 Cr | — |
| Basic Average Shares | 10.46 Cr | 10.46 Cr | 10.46 Cr | 10.46 Cr | — |
| Diluted EPS | 35.52 | 29.45 | 22.95 | 16.72 | — |
| Basic EPS | 35.52 | 29.45 | 22.95 | 16.72 | — |
| Diluted NI Availto Com Stockholders | 371.64 Cr | 308.10 Cr | 240.09 Cr | 174.93 Cr | — |
| Net Income Common Stockholders | 371.64 Cr | 308.10 Cr | 240.09 Cr | 174.93 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 371.64 Cr | 308.10 Cr | 240.09 Cr | 174.93 Cr | — |
| Net Income Including Noncontrolling Interests | 371.64 Cr | 308.10 Cr | 240.09 Cr | 174.93 Cr | — |
| Net Income Continuous Operations | 371.64 Cr | 308.10 Cr | 240.09 Cr | 174.93 Cr | — |
| Tax Provision | 122.91 Cr | 104.46 Cr | 81.93 Cr | 62.59 Cr | — |
| Pretax Income | 494.55 Cr | 412.56 Cr | 322.01 Cr | 237.52 Cr | — |
| Other Non Operating Income Expenses | 44.45 Cr | 33.78 Cr | 1.59 Cr | 0.97 Cr | — |
| Net Non Operating Interest Income Expense | -0.53 Cr | -2.55 Cr | -0.74 Cr | -1.35 Cr | — |
| Interest Expense Non Operating | 0.53 Cr | 2.55 Cr | 4.51 Cr | 5.48 Cr | — |
| Operating Income | 451.96 Cr | 377.97 Cr | 304.75 Cr | 236.13 Cr | — |
| Operating Expense | 442.62 Cr | 409.78 Cr | 328.82 Cr | 294.39 Cr | — |
| Other Operating Expenses | 249.31 Cr | 233.14 Cr | 155.10 Cr | 126.49 Cr | — |
| Depreciation And Amortization In Income Statement | 54.37 Cr | 53.59 Cr | 54.03 Cr | 50.05 Cr | — |
| Depreciation Income Statement | 54.37 Cr | 53.59 Cr | 50.65 Cr | 46.66 Cr | — |
| Gross Profit | 894.57 Cr | 787.74 Cr | 633.57 Cr | 530.52 Cr | — |
| Cost Of Revenue | 305.51 Cr | 229.20 Cr | 197.07 Cr | 177.92 Cr | — |
| Total Revenue | 1.20K Cr | 1.02K Cr | 830.63 Cr | 708.44 Cr | — |
| Operating Revenue | 1.20K Cr | 1.02K Cr | 830.63 Cr | 708.44 Cr | — |
| Total Unusual Items | — | 14.22 Cr | 4.24 Cr | -0.95 Cr | 6.50 Cr |
| Total Unusual Items Excluding Goodwill | — | 14.22 Cr | 4.24 Cr | -0.95 Cr | 6.50 Cr |
| Interest Income | — | 3.04 Cr | 4.44 Cr | 4.79 Cr | 1.79 Cr |
| Rent Expense Supplemental | — | 8.56 Cr | 5.90 Cr | 20000.00 | 40000.00 |
| Special Income Charges | — | 0.15 Cr | 0.53 Cr | -6.18 Cr | -0.48 Cr |
| Other Special Charges | — | -0.15 Cr | -0.53 Cr | -0.27 Cr | -30000.00 |
| Total Other Finance Cost | — | 0.63 Cr | 0.67 Cr | 0.65 Cr | 0.38 Cr |
| Interest Income Non Operating | — | 3.04 Cr | 4.44 Cr | 4.79 Cr | 1.79 Cr |
| Amortization | — | 0.34 Cr | 3.38 Cr | 3.40 Cr | 3.26 Cr |
| Selling General And Administration | — | 44.24 Cr | 34.20 Cr | 32.02 Cr | 20.46 Cr |
| Selling And Marketing Expense | — | 33.11 Cr | 23.70 Cr | 21.44 Cr | 13.36 Cr |
| General And Administrative Expense | — | 11.13 Cr | 10.50 Cr | 10.58 Cr | 7.09 Cr |
| Rent And Landing Fees | — | 8.56 Cr | 5.90 Cr | 20000.00 | 40000.00 |
| Write Off | — | — | 0.00 | 6.45 Cr | 0.49 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Concord Biotech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.